Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients: results of the LE-MON-5 trial
Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, German...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2017
|
| In: |
Annals of hematology
Year: 2017, Jahrgang: 96, Heft: 6, Pages: 887-894 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-017-2983-0 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1007/s00277-017-2983-0 Verlag, Volltext: https://link.springer.com/article/10.1007/s00277-017-2983-0 
|
| Verfasserangaben: | Friederike Braulke, Xenia Schulz, Ulrich Germing, Esther Schuler, Uwe Platzbecker, Florian Nolte, Wolf-Karsten Hofmann, Aristoteles Giagounidis, Katharina Götze, Michael Lübbert, Richard F. Schlenk, Julie Schanz, Ulrike Bacher, Arnold Ganser, Guntram Büsche, Anne Letsch, Philippe Schafhausen, Gesine Bug, Tim H. Brümmendorf, Rainer Haas, Lorenz Trümper, Katayoon Shirneshan, Detlef Haase |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1576535118 | ||
| 003 | DE-627 | ||
| 005 | 20220814170028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180619s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-017-2983-0 |2 doi | |
| 035 | |a (DE-627)1576535118 | ||
| 035 | |a (DE-576)506535118 | ||
| 035 | |a (DE-599)BSZ506535118 | ||
| 035 | |a (OCoLC)1341011897 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Braulke, Friederike |d 1979- |e VerfasserIn |0 (DE-588)131921509 |0 (DE-627)516081012 |0 (DE-576)267176988 |4 aut | |
| 245 | 1 | 0 | |a Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients |b results of the LE-MON-5 trial |c Friederike Braulke, Xenia Schulz, Ulrich Germing, Esther Schuler, Uwe Platzbecker, Florian Nolte, Wolf-Karsten Hofmann, Aristoteles Giagounidis, Katharina Götze, Michael Lübbert, Richard F. Schlenk, Julie Schanz, Ulrike Bacher, Arnold Ganser, Guntram Büsche, Anne Letsch, Philippe Schafhausen, Gesine Bug, Tim H. Brümmendorf, Rainer Haas, Lorenz Trümper, Katayoon Shirneshan, Detlef Haase |
| 264 | 1 | |c 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a First online: 03 April 2017 | ||
| 500 | |a Gesehen am 19.06.2018 | ||
| 520 | |a Transfusion-dependent patients with low- or intermediate-1-risk myelodysplastic syndrome, <5% bone marrow (BM) blasts and isolated 5q-deletion received lenalidomide within the German MDS study group phase-II clinical trial LE-MON-5 (EudraCT:2008-001866-10) of the University of Duesseldorf, Germany. Cytogenetic monitoring was performed by chromosome banding analyses (CBA) of BM cells and fluorescence in situ hybridization (FISH) analyses of peripheral blood (PB) mononuclear CD34+ cells using extended probe panels. Out of 144 patients screened for study enrollment, 24% failed to meet inclusion criteria due to cytogenetic findings. Eighty-seven patients were followed with a median observation time of 30 months. Cytogenetic response detected by FISH and CBA in 74 and 66% of patients, respectively, was predictive for hematologic response as well as of high prognostic relevance. After 2 years, AML rate was 8% for all patients. Karyotype evolution was detected in 21 (FISH)-34% (CBA) of patients associated with significantly shorter AML-free survival. Disease progression was first detectable on the cytogenetic level on average 5-6 months before recurrence of transfusion dependence. Our data show for the first time in a prospective setting that a cytogenetic monitoring from the PB helps to early identify treatment failure and progressive disease in lenalidomide-treated patients to improve clinical management. Trial registration: EudraCT:2008-001866-10 | ||
| 700 | 1 | |a Nolte, Florian |d 1976- |e VerfasserIn |0 (DE-588)1033390348 |0 (DE-627)741150433 |0 (DE-576)380987031 |4 aut | |
| 700 | 1 | |a Hofmann, Wolf-Karsten |d 1967- |e VerfasserIn |0 (DE-588)114154635 |0 (DE-627)691208751 |0 (DE-576)351568336 |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 96(2017), 6, Seite 887-894 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients results of the LE-MON-5 trial |
| 773 | 1 | 8 | |g volume:96 |g year:2017 |g number:6 |g pages:887-894 |g extent:8 |a Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients results of the LE-MON-5 trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00277-017-2983-0 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007/s00277-017-2983-0 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180619 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 50000 |e 50000PS129025380 |k 0/50000/ |p 11 | ||
| 998 | |g 114154635 |a Hofmann, Wolf-Karsten |m 114154635:Hofmann, Wolf-Karsten |d 60000 |d 61200 |e 60000PH114154635 |e 61200PH114154635 |k 0/60000/ |k 1/60000/61200/ |p 7 | ||
| 998 | |g 1033390348 |a Nolte, Florian |m 1033390348:Nolte, Florian |d 60000 |d 61200 |e 60000PN1033390348 |e 61200PN1033390348 |k 0/60000/ |k 1/60000/61200/ |p 6 | ||
| 999 | |a KXP-PPN1576535118 |e 3013046341 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"name":{"displayForm":["Friederike Braulke, Xenia Schulz, Ulrich Germing, Esther Schuler, Uwe Platzbecker, Florian Nolte, Wolf-Karsten Hofmann, Aristoteles Giagounidis, Katharina Götze, Michael Lübbert, Richard F. Schlenk, Julie Schanz, Ulrike Bacher, Arnold Ganser, Guntram Büsche, Anne Letsch, Philippe Schafhausen, Gesine Bug, Tim H. Brümmendorf, Rainer Haas, Lorenz Trümper, Katayoon Shirneshan, Detlef Haase"]},"person":[{"display":"Braulke, Friederike","given":"Friederike","role":"aut","family":"Braulke"},{"family":"Nolte","role":"aut","display":"Nolte, Florian","given":"Florian"},{"family":"Hofmann","role":"aut","given":"Wolf-Karsten","display":"Hofmann, Wolf-Karsten"},{"role":"aut","family":"Schlenk","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich"}],"recId":"1576535118","note":["First online: 03 April 2017","Gesehen am 19.06.2018"],"title":[{"title_sort":"Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients","title":"Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients","subtitle":"results of the LE-MON-5 trial"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"8 S."}],"id":{"doi":["10.1007/s00277-017-2983-0"],"eki":["1576535118"]},"relHost":[{"recId":"253389852","origin":[{"publisher":"Springer","dateIssuedDisp":"1991-","dateIssuedKey":"1991","publisherPlace":"Berlin ; Heidelberg ; New York"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["1458429-3"],"issn":["1432-0584"],"eki":["253389852"]},"title":[{"title_sort":"Annals of hematology","title":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie"}],"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"],"pubHistory":["62, 1 (Februrary 1991)-"],"part":{"text":"96(2017), 6, Seite 887-894","pages":"887-894","extent":"8","issue":"6","volume":"96","year":"2017"},"language":["eng"],"titleAlt":[{"title":"Hematology"}],"disp":"Peripheral blood cytogenetics allows treatment monitoring and early identification of treatment failure to lenalidomide in MDS patients results of the LE-MON-5 trialAnnals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedDisp":"2017","dateIssuedKey":"2017"}]} | ||
| SRT | |a BRAULKEFRIPERIPHERAL2017 | ||